α bungarotoxin α bgt

DMXBA (Abcam, Cambridge, UK), a selective α7nAChR agonist, was dissolved in saline and administered daily by intraperitoneal injection at a dose of 4 mg/kg, beginning on day 10 of CRS. Peripherally administered DMXBA has a biological half-life of 12–24 h [16 (link)] and readily crosses the blood–brain barrier [19 (link)]. In a subgroup, mice were pretreated intraperitoneally with α7nAChR antagonist α-bungarotoxin (α-BGT; 1 μg/kg, Abcam) 15 min before DMXBA treatment. A control group of CRS-exposed mice were administered saline. Normal healthy mice with or without saline treatment served as negative controls. The delivery time and doses of DMXBA and α-BGT were chosen on the basis of our preliminary experiments and relevant references [13 (link), 15 (link), 20 (link)].

CGP 55845 hydrochloride (Tocris, #1248), ±α-Methyl-4-carboxyphenylglycine (Sigma, #M-4796), ANA-12 (Tocris, #4781), D(−)-2-Amino-5-phosphonopentanoic acid (APV; Sigma, #A8054), α-Bungarotoxin (αBGT; Abcam, # ab120542).
sAPPα and sAPPβ production and purification was carried out according to the protocols developed by the Tate lab (Turner et al., 2007 (link)).